文献速递支持与姑息治疗骨软组织肉瘤与黑色素瘤头颈与中枢神经肿瘤

1970-99年诊断的儿童癌症幸存者慢性健康问题风险的时间趋势:儿童癌症幸存者研究队列报告

Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort.
PubMed 文献 · Lancet Oncol · 2018-11-08

该回顾性队列纳入1970-1999年在北美诊断的23 601例儿童癌症5年幸存者,中位随访21年。20年至少一种3-5级慢性疾病累积发病率从1970-79年诊断的33.2%降至1990-99年的27.5%,但髓母细胞瘤/原始神经外胚层肿瘤和神经母细胞瘤的15年累积发病率升高,听力损失增加。

要点

  • 20年至少一种3-5级慢性疾病累积发病率从1970-79年的33.2%降至1990-99年的27.5%。
  • 髓母细胞瘤/原始神经外胚层肿瘤和神经母细胞瘤的15年累积发病率在1990-99年诊断者中更高。
  • 听力损失15年累积发病率从1970-79年的3.0%升至1990-99年的5.7%。

核心结论

  • 结果提示更近期治疗的儿童癌症幸存者健康结局改善,与同期调整治疗方案以最大化总生存并降低长期不良事件风险的努力一致。
  • 继续进步的癌症治疗有望进一步降低儿童癌症幸存者长期不良事件风险。
  • 然而,儿童癌症的长期生存对许多幸存者仍代价不菲,强调对该人群长期随访照护的重要性。

研究设计与样本

  • 儿童癌症幸存者研究(Childhood Cancer Survivor Study)是一项回顾性队列,对北美1970年至1999年诊断、诊断时年龄小于21岁的常见儿童癌症(白血病、中枢神经系统肿瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、Wilms瘤、神经母细胞瘤、软组织肉瘤或骨肿瘤)5年幸存者进行纵向随访。
  • 共纳入23 601例幸存者,中位随访21年(IQR 15-25),另比较5051例同胞。
  • 分析诊断后20年内发生的严重至致死性慢性健康事件的累积发病率,按诊断年代比较;采用多变量回归模型估计每诊断年代的风险比,并加入治疗变量评估治疗变化是否减弱诊断年代与慢性疾病风险的关联。

主要发现

  • 23 601例幸存者中,至少一种3-5级慢性疾病的20年累积发病率从1970-79年诊断者的33.2%(95% CI 32.0-34.3)显著降至1980-89年的29.3%(28.4-30.2;p<0.0001),以及1990-99年的27.5%(26.4-28.6;p=0.012 vs 1980-89)。
  • 5051例同胞的至少一种3-5级慢性疾病20年累积发病率为4.6%(95% CI 3.9-5.2)。
  • 1990-99年诊断者与1970-79年诊断者相比,至少一种3-5级慢性疾病的15年累积发病率更低见于霍奇金淋巴瘤(17.7% [95% CI 15.0-20.5] vs 26.4% [23.8-29.1];p<0.0001)、非霍奇金淋巴瘤(16.9% [14.0-19.7] vs 23.8% [19.9-27.7];p=0.0053)、星形细胞瘤(30.5% [27.8-33.2] vs 47.3% [42.9-51.7];p<0.0001)、Wilms瘤(11.9% [9.5-14.3] vs 17.6% [14.3-20.8];p=0.034)、软组织肉瘤(28.3% [23.5-33.1] vs 36.5% [31.5-41.4];p=0.021)和骨肉瘤(65.6% [60.6-70.6] vs 87.5% [84.1-91.0];p<0.0001)。
  • 相反,1990-99年诊断者与1970-79年诊断者相比,至少一种3-5级慢性疾病的15年累积发病率更高见于髓母细胞瘤或原始神经外胚层肿瘤(58.9% [54.4-63.3] vs 42.9% [34.9-50.9];p=0.00060)和神经母细胞瘤(25.0% [21.8-28.2] vs 18.0% [14.5-21.6];p=0.0045)。
  • 治疗变化作为诊断年代与3-5级慢性疾病风险关联的显著中介因素:星形细胞瘤模型中未纳入治疗时每年代HR=0.77(95% CI 0.64-0.92),纳入治疗后HR=0.89(95% CI 0.72-1.11;pmediation=0.0085);霍奇金淋巴瘤未纳入治疗时HR=0.75(95% CI 0.65-0.85),纳入治疗后HR=0.91(95% CI 0.73-1.12;pmediation=0.024)。

临床怎么用

  • 作者认为,儿童癌症长期生存对许多幸存者仍代价不菲,强调对该人群长期随访照护的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatments for childhood cancer have evolved over the past 50 years, with the goal of maximising the proportion of patients who achieve long-term survival, while minimising the adverse effects of therapy. We aimed to assess incidence patterns of serious chronic health conditions in long-term survivors of childhood cancer across three decades of diagnosis and treatment. METHODS: We used data from the Childhood Cancer Survivor Study, a retrospective cohort with longitudinal follow-up of 5-year survivors of common childhood cancers (leukaemia, tumours of the CNS, Hodgkin lymphoma, non-Hodgkin lymphoma, Wilms tumour, neuroblastoma, soft tissue sarcoma, or bone tumours) who were diagnosed before the age of 21 years and from 1970 to 1999 in North America. We examined the cumulative incidence of severe to fatal chronic health conditions occurring up to 20 years post-diagnosis among survivors, compared by diagnosis decade. We used multivariable regression models to estimate hazard ratios per diagnosis decade, and we added treatment variables to assess whether treatment changes attenuated associations between diagnosis decade and chronic disease risk. FINDINGS: Among 23 601 survivors with a median follow-up of 21 years (IQR 15-25), the 20-year cumulative incidence of at least one grade 3-5 chronic condition decreased significantly from 33·2% (95% CI 32·0-34·3) in those diagnosed 1970-79 to 29·3% (28·4-30·2; p<0·0001) in 1980-89, and 27·5% (26·4-28·6; p=0·012 vs 1980-89) in 1990-99. By comparison, the 20-year cumulative incidence of at least one grade 3-5 condition in 5051 siblings was 4·6% (95% CI 3·9-5·2). The 15-year cumulative incidence of at least one grade 3-5 condition was lower for survivors diagnosed 1990-99 compared with those diagnosed 1970-79 for Hodgkin lymphoma (17·7% [95% CI 15·0-20·5] vs 26·4% [23·8-29·1]; p<0·0001), non-Hodgkin lymphoma (16·9% [14·0-19·7] vs 23·8% [19·9-27·7]; p=0.0053), astrocytoma (30·5% [27·8-33·2] vs 47·3% [42·9-51·7]; p<0·0001), Wilms tumour (11·9% [9·5-14·3] vs 17·6% [14·3-20·8]; p=0·034), soft tissue sarcoma (28·3% [23·5-33·1] vs 36·5% [31·5-41·4]; p=0·021), and osteosarcoma (65·6% [60·6-70·6] vs 87·5% [84·1-91·0]; p<0·0001). By contrast, the 15-year cumulative incidence of at least one grade 3-5 condition was higher (1990-99 vs 1970-79) for medulloblastoma or primitive neuroectodermal tumour (58·9% [54·4-63·3] vs 42·9% [34·9-50·9]; p=0·00060), and neuroblastoma (25·0% [21·8-28·2] vs 18·0% [14·5-21·6]; p=0·0045). Results were consistent with changes in treatment as a significant mediator of the association between diagnosis decade and risk of grade 3-5 chronic conditions for astrocytoma (HR per decade without treatment in the model = 0·77, 95% CI 0·64-0·92; HR with treatment in the model=0·89, 95% CI 0·72-1·11; pmediation=0·0085) and Hodgkin lymphoma (HR without treatment=0·75, 95% CI 0·65-0·85; HR with treatment=0·91, 95% CI 0·73-1·12; pmediation=0·024). Temporal decreases in 15-year cumulative incidence comparing survivors diagnosed 1970-79 to survivors diagnosed 1990-99 were noted for endocrinopathies (5·9% [5·3-6·4] vs 2·8% [2·5-3·2]; p<0·0001), subsequent malignant neoplasms (2·7% [2·3-3·1] vs 1·9% [1·6-2·2]; p=0·0033), musculoskeletal conditions (5·8% [5·2-6·4] vs 3·3% [2·9-3·6]; p<0·0001), and gastrointestinal conditions (2·3% [2·0-2·7] vs 1·5% [1·3-1·8]; p=0·00037), while hearing loss increased (3·0% [2·6-3·5] vs 5·7% [5·2-6·1]; p<0·0001). INTERPRETATION: Our results suggest that more recently treated survivors of childhood cancer had improvements in health outcomes, consistent with efforts over the same time period to modify childhood cancer treatment regimens to maximise overall survival, while reducing risk of long-term adverse events. Continuing advances in cancer therapy offer promise of further reducing the risk of long-term adverse events in childhood cancer survivors. However, achieving long-term survival for childhood cancer continues to come at a cost for many survivors, emphasising the importance of long-term follow-up care for this population. FUNDING: National Cancer Institute and the American Lebanese-Syrian Associated Charities.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Gibson TM, Mostoufi-Moab S, Stratton KL, et al. Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970-99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncol. 2018. PMID: 30416076. doi:10.1016/S1470-2045(18)30537-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。